Skip to Content

Venlafaxine Disease Interactions

There are 11 disease interactions with venlafaxine:

Major

SNRI antidepressants (Includes venlafaxine) ↔ depression

Severe Potential Hazard, Moderate plausibility. Applies to: Bipolar Disorder, Depression

Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes. Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset. It may be prudent to refrain from dispensing large quantities of medication to these patients.

Major

SNRI antidepressants (Includes venlafaxine) ↔ renal disease

Severe Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

The clearance of SNRI antidepressants is decreased in subjects with renal impairment. SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment. The use of SNRIs is not recommended in patients with end-stage renal disease.

Major

Venlafaxine (Includes venlafaxine) ↔ renal/liver disease

Severe Potential Hazard, High plausibility. Applies to: Renal Dysfunction, Liver Disease

Venlafaxine is metabolized by the liver, and both the parent drug and metabolites are excreted by the kidney. Patients with renal and/or liver disease may be at greater risk for adverse effects from venlafaxine due to decreased drug clearance. Therapy with venlafaxine should be administered cautiously in patients with impaired renal and/or hepatic function. A reduction in the total daily dosage is recommended. The manufacturer suggests a 50% reduction in patients with moderate hepatic impairment (possibly more in patients with cirrhosis), a 25% reduction in patients with mild to moderate renal impairment, and a 50% reduction in patients undergoing hemodialysis (to be administered after dialysis treatment).

References

  1. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST "Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite." J Clin Pharmacol 32 (1992): 716-24
Moderate

Antidepressants (Includes venlafaxine) ↔ mania

Moderate Potential Hazard, Moderate plausibility. Applies to: Mania, Bipolar Disorder

All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder. Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.

References

  1. Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993): s45-50
  2. Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988): 804-8
  3. Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991): 141-4
  4. Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987): 423-4
  5. "Product Information. Desyrel (trazodone)." Bristol-Myers Squibb, Princeton, NJ.
  6. Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991): 275-8
  7. Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S "Trazodone-induced mania." Br J Psychiatry 149 (1986): 787-9
  8. Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991): 233-6
  9. Dubin H, Spier S, Giannandrea P "Nefazodone-induced mania." Am J Psychiatry 154 (1997): 578-9
  10. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  11. "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb, Princeton, NJ.
  12. Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987): 274-5
  13. Jeffries JJ, Aljeshi A "Nefazodone-induced mania." Can J Psychiatry 40 (1995): 218
  14. "Product Information. Remeron (mirtazapine)." Organon, West Orange, NJ.
  15. Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986): 1482-3
  16. Warren M, Bick PA "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984): 1103-4
  17. Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995): 37-45
View all 17 references
Moderate

SNRI antidepressants (Includes venlafaxine) ↔ glaucoma

Moderate Potential Hazard, Moderate plausibility. Applies to: Glaucoma (Narrow Angle)

SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.

Moderate

SNRI antidepressants (Includes venlafaxine) ↔ hypertension

Moderate Potential Hazard, Moderate plausibility. Applies to: Hypertension

Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure. Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension. Blood pressure should be assessed prior to initiating treatment and monitored regularly. The dose should be reduced or discontinued if necessary.

References

  1. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994): 99-106
  3. Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30
Moderate

SNRI antidepressants (Includes venlafaxine) ↔ hyponatremia

Moderate Potential Hazard, Moderate plausibility. Applies to: Hyponatremia, Dehydration

Treatment with SNRI antidepressants can cause hyponatremia. Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.

Moderate

SNRI antidepressants (Includes venlafaxine) ↔ mania

Moderate Potential Hazard, Moderate plausibility. Applies to: Mania, Bipolar Disorder

Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.

Moderate

SNRI antidepressants (Includes venlafaxine) ↔ seizures

Moderate Potential Hazard, Moderate plausibility. Applies to: Seizures

SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.

References

  1. Schlienger RG, Klink MH, Eggenberger C, Drewe J "Seizures associated with therapeutic doses of venlafaxine and trimipramine." Ann Pharmacother 34 (2000): 1402-5
  2. Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991): 233-6
  3. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  4. Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991): 141-4
View all 4 references
Moderate

SNRI antidepressants (Includes venlafaxine) ↔ urinary tract obstruction

Moderate Potential Hazard, Moderate plausibility. Applies to: Urinary Tract Infection, Urinary Tract Obstruction

SNRI antidepressants have a noradrenergic effect and can affect urethral resistance. Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.

Moderate

Venlafaxine (Includes venlafaxine) ↔ weight loss

Minor Potential Hazard, Moderate plausibility. Applies to: Weight Loss/Failure to Thrive, Anorexia/Feeding Problems, Malnourished

The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss. The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo. Anorexia may occur in approximately 10% of patients. Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.

References

  1. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994): 99-106

Venlafaxine drug interactions

There are 1161 drug interactions with venlafaxine

Venlafaxine alcohol/food interactions

There are 2 alcohol/food interactions with venlafaxine

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide